Feature

Impax Heads To Rare Trial In Pay-For-Delay Case

Law360 (March 9, 2018, 10:04 PM EST) -- Impax Laboratories Inc. is set to face a Massachusetts jury Monday over allegations it received illegal reverse payments from Medicis Pharmaceutical Corp. to delay a generic form of acne medication Solodyn, one of just a handful of pay-for-delay cases to approach a verdict since the Supreme Court's landmark Actavis ruling in 2013.

Here, Law360 breaks down what's at stake in the case and why attorneys are watching.

Why Few Pay-For-Delay Cases Make It to Trial

Pay-for-delay litigation has largely hinged on the high court's decision in Federal Trade Commission v. Actavis since the ruling was handed down in 2013. In that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!